Kiora appoints Keith Lane as EVP of Clinical Development and Regulatory Affairs

KIORA PHARMACEUTICALS INC

Lane appointed EVP, Head of Clinical Development and Regulatory Affairs effective Sept 8, 2026.
Compensation: $350k base salary, $75k sign-on bonus, 35% base target bonus, 55k share option grant.
Lane brings 20+ yrs ophthalmic experience from Ora; oversaw 60+ trials, incl. 12 global Phase 3 studies.
Will lead U.S./global clinical development for KIO-301 (retinitis pigmentosa) and other pipeline assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.